Dermira (DERM) Misses Q2 EPS by 3c, reaffirms FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
B.Riley Reiterates Buy Rating on Journey Medical Corp. (DERM)
August 13, 2024 6:55 AM EDTB.Riley analyst Kalpit Patel reiterated a Buy rating and $8.00 price target on Journey Medical Corp. (NASDAQ: DERM).
The analyst comments "Journey Medical (DERMBuy, $8 PT) reported 2Q earnings, with top-line revenues of $14.9M (vs. our $13.3M estimate), likely signaling stabilization in its dermatology-focused... More
